Mutational Landscape of HER2-low Breast Carcinoma

被引：0
|
作者：
Lukose, Georgi [1 ]
Munoz-Zuluaga, Carlos [1 ]
Munoz-Arcos, Laura [2 ]
Michaud, Olivier [2 ]
Cristofanilli, Massimo [1 ]
Hoda, Syed [3 ]
Solomon, James [1 ]
机构：
[1] New York Presbyterian Weill Cornell Med, New York, NY USA
[2] New York Presbyterian Weill Cornell Med Ctr, New York, NY USA
[3] Weill Cornell Med, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
186
引用
收藏
页码：S176 / S177
页数：2
相关论文
共 50 条
  • [21] HER2-Low Breast Cancer: a New Subtype?
    Corti, Chiara
    Giugliano, Federica
    Nicolo, Eleonora
    Tarantino, Paolo
    Criscitiello, Carmen
    Curigliano, Giuseppe
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (05) : 468 - 478
  • [22] HER2-Low Breast Cancer: Now and in the Future
    Kang, Sora
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 700 - 720
  • [23] Clinicopathological Features and Fluorescent in Situ Hybridization Profile of HER2-Low Breast Carcinoma
    Hu, Yan
    Jones, Dan
    Zhao, Weiqiang
    Tozbikian, Gary
    Parwani, Anil
    Li, Zaibo
    LABORATORY INVESTIGATION, 2023, 103 (03) : S145 - S146
  • [24] HER2-low vs HER2-zero metastatic breast carcinoma: A clinical and genomic descriptive analysis
    Sanchez Bayona, R.
    Luna, A. M.
    Tolosa, P.
    Sanchez De Torre, A.
    Castelo, A.
    Marin, M.
    Garcia, C.
    Boni, V.
    Bernal Hertfelder, E.
    Vega, E.
    Rojas, B.
    Bratos, R.
    Martinez, M.
    Diaz Bermejo, A. J.
    Lema, L.
    Manso, L.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S29 - S30
  • [25] The clinicopathological and prognostic significance of HER2-low breast cancer: A comparative analysis between HER2-low and HER2-zero subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CANCER RESEARCH, 2024, 84 (09)
  • [26] The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes
    Nishimura, Reiki
    Fujiki, Yoshitaka
    Taira, Tetsuhiko
    Miyaki, Toshiko
    Kanemitsu, Shuichi
    Yotsumoto, Daisuke
    Teraoka, Megumi
    Kawano, Junko
    Gondo, Naomi
    Mitsueda, Reiko
    Baba, Shinichi
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yoshiaki
    Sagara, Yasuaki
    CLINICAL BREAST CANCER, 2024, 24 (05) : 431 - 438
  • [27] Improving HER2 testing reproducibility in HER2-low breast cancer
    Sajjadi, Elham
    Venetis, Konstantinos
    Ivanova, Mariia
    Fusco, Nicola
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 882 - 888
  • [28] HER2-Low Breast Cancer Can Be Visualized by HER2 PET
    Altena, Renske
    af Buren, Siri
    Tran, Thuy
    Axelsson, Rimma
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1842 - 1842
  • [29] HER2-Low expression in primary male breast cancer
    Rudlowski, Christian
    Erices-Leclercq, Melanie
    Nobbe, Katleen
    Baldus, Stephan
    Foerster, Robert
    Foerster, Frank
    Lubig, Sabine
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 29 - 29
  • [30] Comprehensive genomic characterization of HER2-low breast cancer
    Tarantino, Paolo
    Gupta, Hersh V.
    Hughes, Melissa E.
    Files, Janet L.
    Strauss, Sarah
    Kirkner, Gregory
    Feeney, Anne-Marie
    Li, Yvonne Y.
    Garrido-Castro, Ana C.
    Barroso-Sousa, Romualdo
    Bychkovsky, Brittany
    MacConaill, Laura
    Lindeman, Neal
    Johnson, Bruce
    Meyerson, Matthew
    Kabraji, Sheheryar
    Jeselsohn, Rinath
    Qiu, Xintao
    Li, Rong
    Long, Henry W.
    Winer, Eric
    Dillon, Deborah A.
    Curigliano, Giuseppe
    Cherniack, Andrew
    Tolaney, Sara
    Lin, Nancy U.
    CANCER RESEARCH, 2023, 83 (05)
12345